Published • loading... • Updated
Trop-2 Antibody-Drug Conjugate Improves Survival in Recurrent Endometrial Cancer
- On Monday, October 26, 2026, researchers presented phase 3 trial results at the European Society For Medical Oncology showing sacituzumab tirumotecan reduced death risk by 32% in patients with advanced endometrial cancer.
- Endometrial cancer incidence in UK women under 50 has doubled over 25 years, driven largely by the obesity epidemic and associated hormonal imbalances that experts say fuel rapid cell division.
- The trial involved 776 women with advanced disease; 35.1% treated with sac-TMT experienced tumor shrinkage versus 17.3% on standard chemotherapy, while the drug cut progression risk by 41%.
- Study principal investigator Dr. Bhavana Pothuri stated the results establish sac-TMT as a "new standard treatment" for recurrent endometrial cancer and suggest effectiveness against other cancers where Trop-2 protein is overexpressed.
- Merck is conducting 18 global Phase 3 studies, including 10 focused on women's cancers, to support regulatory approvals in the United States, Europe, and elsewhere outside China.
Insights by Ground AI
41 Articles
41 Articles
MarketBeatReposted by 
thecerbatgem.com
thecerbatgem.comMerck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts
Merck & Co., Inc. (NYSE:MRK) outlined new oncology data and development plans at the European Society for Medical Oncology annual meeting, highlighting phase III results for its sacituzumab tirumotecan, or sac-TMT, antibody-drug conjugate in endometrial cancer and its individualized neoantigen t
·Sioux Falls, United States
Read Full Article
Merck Drug Boosts Survival From Hard-to-Treat Uterine Cancer
An experimental drug from Merck & Co. helped women with advanced endometrial cancer live significantly longer than those receiving chemotherapy, bolstering the company’s ambitions for the novel treatment it is studying in a wide range of tumors.
·New York, United States
Read Full Article
Merck's therapy extends survival in hard-to-treat uterine cancer ...
·London, United Kingdom
Read Full ArticleCoverage Details
Total News Sources41
Leaning Left1Leaning Right5Center10Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
C 63%
R 31%
Factuality
To view factuality data please Upgrade to Premium
